Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk, after the company lost its first mover ...

Chugai Pharmaceutical Co. Ltd. (OTC:CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s ...

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...

S&P 500, Eli Lilly and Company, Novo Nordisk A/S Class B, Novo Nordisk A/S. Read 's Market Analysis on Investing.com ...

Investing.com -- Parvus Asset Management, a London-based activist hedge fund, is acquiring a stake in Danish pharmaceutical company Novo Nordisk (NYSE: NVO ), according to The Financial Times. The ...

Eli Lilly & Co. sees 60% sales increase for weight-loss drug in India, tapping into growing demand for anti-obesity solutions ...

Metsera has linked its amylin analog to 8.4% placebo-adjusted weight loss at Day 36, advancing its push to develop an ...

Since its launch in late March, Mounjaro sales have trebled. Winselow Tucker, president and general manager of Lilly in India ...

Metsera Inc.’s shares jumped after the obesity startup shared better-than-expected data on a weight-loss shot that would ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...